UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients

Therapeutic Drug Monitoring

Volumn 34, Issue 6, 2012, Pages 671-679

  Fukuda, Tsuyoshi ^a   Goebel, Jens ^b   Cox, Shareen ^a   Maseck, Denise ^a   Zhang, Kejian ^a,c   Sherbotie, Joseph R ^d   Ellis, Eileen N ^e   James, Laura P ^f   Ward, Robert M ^d   Vinks, Alexander A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b Division of Nephrology and Hypertension   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f ARKANSAS CHILDREN S HOSPITAL   (United States)

Author keywords

kidney transplantation; multidrug resistance associated protein 2; mycophenolate mofetil; mycophenolic acid; pediatric patient; pharmacogenetics; pharmacokinetics; uridine diphosphate glucuronosyltransferase

Indexed keywords

CORTICOSTEROID; GENOMIC DNA; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; MULTIDRUG RESISTANCE PROTEIN 2; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); DNA EXTRACTION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EXPOSURE; FEMALE; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; GRAFT RECIPIENT; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; MAINTENANCE THERAPY; MALE; MAXIMUM PLASMA CONCENTRATION; PEDIATRICS; PHARMACOGENETICS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; BIOTRANSFORMATION; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE; FEMALE; GENETIC ASSOCIATION STUDIES; GLUCURONOSYLTRANSFERASE; HETEROZYGOTE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MYCOPHENOLIC ACID; POLYMORPHISM, SINGLE NUCLEOTIDE; PRODRUGS; PROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84870060943     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182708f84     Document Type: Article

References (44)

1. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455. (Pubitemid 28273453)
2. Kuypers DR, Vanrenterghem Y, Squifflet JP, et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit. 2003;25:609-622.
3. Group EMMCS. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet. 1995;345:1321-1325.
4. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokineticpharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64:672-683.
5. Shaw LM, Korecka M, Venkataramanan R, et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant. 2003;3:534-542.
6. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit. 2006;28: 145-154.
7. Kuypers DR, Le Meur Y, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol. 2010;5:341-358.
8. Ettenger R, Sarwal MM. Mycophenolate mofetil in pediatric renal transplantation. Transplantation. 2005;80(2 suppl):S201-S210. (Pubitemid 41552907)
9. Tonshoff B, David-Neto E, Ettenger R, et al. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation. Transplant Rev (Orlando). 2011;25:78-89.
10. Tett SE, Saint-Marcoux F, Staatz CE, et al. Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplant Rev (Orlando). 2011;25:47-57.
11. Kuypers DR, Naesens M, Vermeire S, et al. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther. 2005;78:351-361.
12. Baldelli S, Merlini S, Perico N, et al. C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics. 2007;8:1127-1141.
13. Levesque E, Delage R, Benoit-Biancamano MO, et al. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin Pharmacol Ther. 2007;81:392-400.
14. Cattaneo D, Merlini S, Zenoni S, et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant. 2005;5:2937-2944.
15. Braun F, Schocklmann H, Ziegler E, et al. Increased mycophenolic acid exposure in stable kidney transplant recipients on tacrolimus as compared with those on sirolimus: implications for pharmacokinetics. Clin Pharmacol Ther. 2009;86:411-415.
16. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol. 2000;14:100-104.
17. Mackenzie PI. Identification of uridine diphosphate glucuronosyltransferases involved in the metabolism and clearance of mycophenolic acid. Ther Drug Monit. 2000;22:10-13.
18. Picard N, Ratanasavanh D, Premaud A, et al. Identification of the UDPglucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005;33:139-146.
19. Girard H, Court MH, Bernard O, et al. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics. 2004;14:501-515.
20. Bernard O, Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos. 2004;32:775-778.
21. Djebli N, Picard N, Rerolle JP, et al. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet Genomics. 2007;17:321-330.
22. Strassburg CP, Strassburg A, Nguyen N, et al. Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus. Biochem J. 1999;338 (pt 2):489-498.
23. Villeneuve L, Girard H, Fortier LC, et al. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther. 2003;307:117-128.
24. Bernard O, Tojcic J, Journault K, et al. Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid. Drug Metab Dispos. 2006;34:1539-1545.
25. Johnson LA, Oetting WS, Basu S, et al. Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors. Eur J Clin Pharmacol. 2008;64:1047-1056.
26. Prausa SE, Fukuda T, Maseck D, et al. UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients. Clin Pharmacol Ther. 2009;85: 495-500.
27. Sherwin CM, Fukuda T, Brunner HI, et al. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011;50:1-24.
28. Hesselink DA, van Hest RM, Mathot RA, et al. Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-Associated protein 2. Am J Transplant. 2005;5:987-994.
29. Westley IS, Brogan LR, Morris RG, et al. Role of MRP2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. Drug Metab Dispos. 2006;34:261-266.
30. Suzuki H, Sugiyama Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv Drug Deliv Rev. 2002;54:1311-1331.
31. Naesens M, Kuypers DR, Verbeke K, et al. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation. 2006;82:1074-1084.
32. Fukuda T, Goebel J, Thogersen H, et al. Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. J Clin Pharmacol. 2011;51:309-320.
33. Premaud A, Debord J, Rousseau A, et al. A double absorption-phase model adequately describes mycophenolic Acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin Pharmacokinet. 2005;44:837-847.
34. Premaud A, Le Meur Y, Debord J, et al. Maximum a posteriori bayesian estimation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit. 2005;27: 354-361.
35. Cox SL, Cabovska B, Vinks AA. Determination of mycophenolic acid and mycophenolic acid glucuronide in human plasma using solid phase extraction and HPLC. Ther Drug Monit. 2005;27:215-216.
36. Shipkova M, Niedmann PD, Armstrong VW, et al. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem. 1998;44:1481-1488.
37. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.
38. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24:25-36.
39. Schwartz GJ, Haycock GB, Edelmann CM Jr, et al. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics. 1976;58:259-263.
40. Young SS, Ge N. Recursive partitioning analysis of complex disease pharmacogenetic studies. I. Motivation and overview. Pharmacogenomics. 2005;6:65-75.
41. Zhao W, Fakhoury M, Deschenes G, et al. Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-Transplant patients. J Clin Pharmacol. 2010;50:1280-1291.
42. de Winter BC, Mathot RA, Sombogaard F, et al. Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. Clin J Am Soc Nephrol. 2011;6:656-663.
43. Levesque E, Benoit-Biancamano MO, Delage R, et al. Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers. Pharmacogenomics. 2008;9:869-879.
44. Soars MG, Petullo DM, Eckstein JA, et al. An assessment of udpglucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos. 2004;32:140-148.